Abstract
Objective: The use of immune-therapeutics in gynecologic oncology patients challenges our traditional paradigm of how to assess disease response rates. Historically patients have worse PFS with each subsequent regimen of treatment. In other malignancies, a PFS ratio (PFSr) has been proposed as a marker of response. If the PFSr is <1, there is an improvement in predicted response. We sought to utilize the PFSr to assess disease response. In addition, we hypothesized that use of immunotherapy alters a patient's response to subsequent therapies by altering either the immune profile of the tumor or immune response of the patient. Our objective was to look at the PFSr of pre- and post-immunotherapy treatments in patients with gynecologic malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
